menu
    • menu
    [{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Golexanolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karolinska Development AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Development AB \/ Undisclosed"},{"orgOrder":0,"company":"Umecrine Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Golexanolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Umecrine Cognition","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Umecrine Cognition \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Umecrine Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Umecrine Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Golexanolone","moa":"GABAA receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Umecrine Cognition","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Umecrine Cognition \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Umecrine Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWEDEN","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Golexanolone","moa":"GABAA receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karolinska Development AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Development AB \/ Undisclosed"},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Golexanolone","moa":"GABAA receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karolinska Development AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Development AB \/ Undisclosed"},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Golexanolone","moa":"GABAA receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karolinska Development AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Development AB \/ Undisclosed"},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Aprea Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"APR-548","moa":"p53","graph1":"Oncology","graph2":"Phase I","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karolinska Development AB \/ Karolinska Development AB","highestDevelopmentStatusID":"6","companyTruncated":"Karolinska Development AB \/ Karolinska Development AB"},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"XNK Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2021","type":"Collaboration","leadProduct":"Evencaleucel","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Karolinska Development AB \/ XNK Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Development AB \/ XNK Therapeutics"},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tafoxiparin","moa":"Uterine contractility","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Karolinska Development AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Development AB \/ Undisclosed"},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tafoxiparin","moa":"Uterine contractility","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Karolinska Development AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Development AB \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Karolinska Development AB

    Menu

    Karolinska Development AB

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Karolinska Development AB

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Karolinska Development AB

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Golexanolone

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Karolinska Development’s Portfolio Company Umecrine Cognition Presents Positive Results From a Preclinical S...

                            Details : Study results show that treatment with Golexanolone (GR3027) for 7 days significantly reduced fatigue in test group compared to the control group (p<0.05). Further analysis shows that treatment also improved other CNS symptoms.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            September 28, 2022

                            Lead Product(s) : Golexanolone

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Karolinska Development AB

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Karolinska Development AB

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Golexanolone

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Karolinska Development’s Portfolio Company Umecrine Cognition Secures Funding Ahead of Phase 2 Study of Gole...

                            Details : Results from previous clinical and pre-clinical studies strongly indicate that GR3027 (golexanolone) is able to counteract such inappropriate suppression of brain activity.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            September 14, 2022

                            Lead Product(s) : Golexanolone

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Karolinska Development AB

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Karolinska Development AB

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Golexanolone

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Karolinska Development’s Portfolio Company Umecrine Cognition Presents New Data Supporting the Development o...

                            Details : Golexanolone, a novel drug candidate that counter acts the effect of allopregnanolone on GABAA receptors, thereby restoring normal nerve signalling in the brain.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            November 03, 2021

                            Lead Product(s) : Golexanolone

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Karolinska Development AB

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Karolinska Development AB

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafoxiparin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Karolinska Development’s Portfolio Company Dilafor Recruits First Patient to Phase 2a Study of Tafoxiparin i...

                            Details : The pregnant women will be randomized to either subcutaneous injection of tafoxiparin and standard of care or only standard of care, which is usually symptomatic treatment with anti-hypertensive drugs.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 27, 2021

                            Lead Product(s) : Tafoxiparin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Karolinska Development AB

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Karolinska Development AB

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafoxiparin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Karolinska Development’s Portfolio Company Dilafor Presents Positive Results from A Phase 2b Study of Tafoxi...

                            Details : The primary objective of the study was to document the effect of tafoxiparin on cervical ripening measured as the degree of ripening according to an internationally established scale, the Bishop score.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 01, 2021

                            Lead Product(s) : Tafoxiparin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Karolinska Development AB

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Karolinska Development AB

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evencaleucel,Isatuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : XNK Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            XNK Therapeutics Partners with Karolinska Institutet on Phase II Study in Patients with Multiple Myeloma with ...

                            Details : The collaboration aims to conduct a Phase II clinical study to treat patients with multiple myeloma using XNK’s leading drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa (isatuximab).

                            Product Name : CellProtect

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            February 26, 2021

                            Lead Product(s) : Evencaleucel,Isatuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : XNK Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Karolinska Development AB

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Karolinska Development AB

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APR-548

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Aprea Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Karolinska Development's portfolio company Aprea Therapeutics receives FDA clearance to initiate Phase 1 study...

                            Details : Aprea Therapeutics intends to initiate a Phase 1 clinical trial of APR-548 in MDS to expand its leadership in the development of therapeutic options for patients with p53 mutated cancers.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 07, 2020

                            Lead Product(s) : APR-548

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Aprea Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Umecrine Cognition

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Umecrine Cognition

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Golexanolone

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Karolinska Development’s Portfolio Company Umecrine Cognition Presents Data from Clinical Phase 2a Study at ...

                            Details : Umecrine Cognition will present the results from its recently conducted clinical phase 2a study of the drug candidate golexanonole, that is in clinical development for hepatic encephalopathy.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            September 02, 2020

                            Lead Product(s) : Golexanolone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Umecrine Cognition

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Umecrine Cognition

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Golexanolone

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Karolinska Development’s Portfolio Company Umecrine Cognition Presents Positive Additional Results From A Ph...

                            Details : Analyses of data for additional efficacy endpoints reveal that treatment with the golexanolone exerts a significant effect on brain signaling with a positive effect on excessive daytime sleepiness.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            May 08, 2020

                            Lead Product(s) : Golexanolone

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Karolinska Development AB

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Karolinska Development AB

                            Sweden arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Golexanolone

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Karolinska Development’s portfolio company Umecrine Cognition announces results from a phase 2a clinical stu...

                            Details : Results demonstrate a positive safety and tolerability profile; however, no indications of clinical effects could be observed.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            April 03, 2020

                            Lead Product(s) : Golexanolone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth